Cascinu S et al. Tumor response and symptom palliation from RAINBOW, a phase III trial of ramucirumab plus paclitaxel in previously treated advanced gastric cancer. Oncologist 2021;26(3):e414-24. Abstract
Catenacci DVT et al. FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma (GC). ASCO 2021;Abstract 4010.
Chao J et al. Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061 and KEYNOTE-062 clinical trials. JAMA Oncol 2021;7(6):895-902. Abstract
Chau I et al. Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): Expanded efficacy and safety analyses from CheckMate 648. ASCO 2022;Abstract 4035.
Cohen DJ et al. A randomized phase 3 study evaluating the efficacy and safety of first-line pembrolizumab plus lenvatinib plus chemotherapy versus chemotherapy in patients with advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015. Gastrointestinal Cancers Symposium 2022;Abstract TPS369.
Doki Y et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med 2022;386(5):449-62. Abstract
Fuchs CS et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014;383(9911):31-9. Abstract
Janjigian YY et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial. Lancet 2021;398(10294):27-40. Abstract
Janjigian YY et al. MATTERHORN: Efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer—A randomized, double-blind, placebo-controlled, phase 3 study. ASCO 2021;Abstract TPS4151.
Janjigian YY et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature 2021;600(7890):727-30. Abstract
Janjigian YY et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric and gastroesophageal junction cancer: Initial findings for the global phase 3 KEYNOTE-811 study. ASCO 2021;Abstract 4013.
Kelley RK et al. Phase 2 open-label study of pembrolizumab plus lenvatinib and belzutifan in patients with advanced solid tumors. ASCO 2022;Abstract TPS4173.
Kelly RJ et al. Adjuvant nivolumab (nivo) in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): Expanded efficacy and safety analyses from CheckMate 577. ASCO 2021;Abstract 4003.
Kelly RJ et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. New Engl J Med 2021;384(13):1191-203. Abstract
Klempner SJ et al. Phase II study of zolbetuximab plus pembrolizumab in claudin 18.2: Positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)—ILUSTRO cohort 3. ASCO GI 2021;Abstract TPS260.
Kroese TE et al. Definition of oligometastatic esophagogastric cancer and impact of local oligometastasis-directed treatment: A systematic review and meta-analysis. Eur J Cancer 2022;166:254-69. Abstract
Lee K-W et al. Association of tumor mutational burden with efficacy of pembrolizumab +/- chemotherapy as first-line therapy for gastric cancer in the phase III KEYNOTE-062 study. Clin Cancer Res 2022;[Online ahead of print]. Abstract
Lordick F. Invited Discussant LBA7. ESMO 2021;Abstract LBA7.
Lorenzen S et al. FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel – Results from a phase II RAMIRIS study of the German Gastric Cancer Study Group at AIO. Eur J Cancer 2022;165:48-57. Abstract
Luo H et al. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: The ESCORT-1st randomized clinical trial. JAMA 2021;326(10):916-25. Abstract
Mansoor W et al. Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: A subgroup analysis from the phase 3 TAGS study. Gastric Cancer 2021;24(4):970-7. Abstract
Metges J-P et al. First-line pembrolizumab plus chemotherapy versus chemotherapy in advanced esophageal cancer: Longer-term efficacy, safety, and quality-of-life results from the phase 3 KEYNOTE-590 study. Gastrointestinal Cancers Symposium 2022;Abstract 241.
Sahin U et al. FAST: A randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol 2021;32(5):609-19. Abstract
Shah MA et al. Zolbetuximab + CAPOX versus CAPOX in first-line treatment of claudin18.2+/HER2– advanced/metastatic gastric or gastroesophageal junction adenocarcinoma: GLOW phase 3 study. Gastrointestinal Cancers Symposium 2022;Abstract TPS365.
Shen L et al. Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: First results of the phase III ORIENT-15 study. ESMO 2021;Abstract LBA52.
Shitari K et al. Exploratory biomarker analysis of trastuzumab deruxtecan in DESTINY-Gastric01, a randomized, phase 2, multicenter, open-label study in patients with HER2-positive or -low advanced gastric or gastroesophageal junction adenocarcinoma. ESMO 2021;Abstract O-14.
Shitara K et al. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature 2022;603(7903):942-8. Abstract
Shitara K et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2018:19(11):1437-48. Abstract
Sun J-M et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): A randomised, placebo-controlled, phase 3 study. Lancet 2021;398(10302):759-71. Abstract
Van Cutsem E et al. Primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen. ESMO 2021;Abstract LBA55.
Wainberg ZA et al. Trial in progress: Phase 1b/3 study of bemarituzumab + mFOLFOX6 + nivolumab versus placebo + mFOLFAX6 + nivolumab in previously untreated advanced gastric and gastroesophageal junction (GEJ) cancer with FGFR2b overexpression (FORTITUDE-102). ASCO 2022;Abstract TPS4165.
Wang Z-X et al. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. Canc Cell 2022;40(3):277-88.e3. Abstract
Wilke H et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): A double-blind, randomised phase 3 trial. Lancet Oncol 2014;15(11):1224-35. Abstract
Xu J et al. Sintilimab plus chemotherapy (chemo) versus chemo as the first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16). ESMO 2021;Abstract LBA53.
Yamaguchi K et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01). ASCO 2022;Abstract 4048.